Navigation Links
Gen-Probe to Webcast Three Upcoming Investor Presentations
Date:2/24/2011

SAN DIEGO, Feb. 24, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at three upcoming investor conferences:

  • RBC Capital Markets' Healthcare Conference in New York at 10 a.m. Eastern Time (ET) on March 2.  The Company also will participate in a panel discussion entitled The Future of Molecular Testing at 3:35 p.m. ET the same day.
  • Cowen and Company's 31st Annual Healthcare Conference in Boston at 10:15 a.m. ET on March 9.
  • Barclays Capital's 2011 Global Healthcare Conference in Miami at 3:15 p.m. ET on March 16.

  • The presentations and the panel discussion will be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at www.gen-probe.com.  The webcasts will be available for 30 days following the events.

    About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

    Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.Contact:Paula IzidoroInvestor Relations858-410-8904
    '/>"/>

    SOURCE Gen-Probe Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
    2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
    3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
    4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
    5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
    6. Gen-Probe to Webcast Two Upcoming Investor Presentations
    7. Neogen Acquires Gen-Probes BioKits Food Safety Business
    8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
    9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
    10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
    11. Gen-Probe to Webcast Two Upcoming Investor Presentations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
    (Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
    (Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
    (Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
    Breaking Medicine News(10 mins):